HomeCompareGGDVY vs JNJ

GGDVY vs JNJ: Dividend Comparison 2026

GGDVY yields 4.39% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $9.2K in total portfolio value· pulled ahead in Year 7
10 years
GGDVY
GGDVY
● Live price
4.39%
Share price
$47.97
Annual div
$2.10
5Y div CAGR
-33.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.1K
Annual income
$7.60
Full GGDVY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — GGDVY vs JNJ

📍 JNJ pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGGDVYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GGDVY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GGDVY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GGDVY
Annual income on $10K today (after 15% tax)
$372.77/yr
After 10yr DRIP, annual income (after tax)
$6.46/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,979.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GGDVY + JNJ for your $10,000?

GGDVY: 50%JNJ: 50%
100% JNJ50/50100% GGDVY
Portfolio after 10yr
$25.7K
Annual income
$2,348.50/yr
Blended yield
9.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GGDVY
No analyst data
Altman Z
2.1
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GGDVY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGGDVYJNJ
Forward yield4.39%2.13%
Annual dividend / share$2.10$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-33.8%28%
Portfolio after 10y$21.1K$30.3K
Annual income after 10y$7.60$4,689.40
Total dividends collected$871.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GGDVY vs JNJ ($10,000, DRIP)

YearGGDVY PortfolioGGDVY Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,990$290.33$10,592$272.30+$398.00GGDVY
2$11,957$197.41$11,289$357.73+$668.00GGDVY
3$12,927$132.88$12,123$472.89+$804.00GGDVY
4$13,921$88.88$13,141$629.86+$780.00GGDVY
5$14,954$59.22$14,408$846.81+$546.00GGDVY
6$16,041$39.36$16,021$1,151.60+$20.00GGDVY
7← crossover$17,189$26.12$18,122$1,588.22$933.00JNJ
8$18,410$17.32$20,930$2,228.20$2.5KJNJ
9$19,710$11.47$24,792$3,191.91$5.1KJNJ
10$21,098$7.60$30,274$4,689.40$9.2KJNJ

GGDVY vs JNJ: Complete Analysis 2026

GGDVYStock

Guangdong Investment Limited, an investment holding company, engages in water resources, property investment and development, department store operation, energy project operation, road and bridge operation, and hotel businesses. Its Water Resources segment provides water distribution, sewage treatment, infrastructure and water pipeline installation services, as well as constructs water supply and sewage treatment infrastructure in Mainland China and Hong Kong. The company's Property Investment and Development segment invests in various properties in Hong Kong and Mainland China; and develops and sells properties in Mainland China. This segment also provides property management services for various commercial properties. Its Department Stores segment operates department stores in Mainland China. The company's Electric Power Generation segment operates coal-fired power plants that supply electricity and steam in the Guangdong province, Mainland China. The company's Hotel Operation and Management segment operate hotels and provides hotel management services to third parties in Hong Kong and Mainland China. As of December 31, 2021, this segment managed 27 hotels, including 3 in Hong Kong, 1 in Macau, and 23 in Mainland China. Its Road and Bridge segment invests in various road and bridge projects, which engages in the toll road operation and road management in Mainland China. The company's Others segment provides treasury services in Hong Kong and Mainland China, as well as corporate and other related services. The company was formerly known as Union Globe Development Limited and changed its name to Guangdong Investment Limited in January 1987. The company was incorporated in 1973 and is based in Central, Hong Kong. Guangdong Investment Limited is a subsidiary of GDH Limited.

Full GGDVY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this GGDVY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GGDVY vs SCHDGGDVY vs JEPIGGDVY vs OGGDVY vs KOGGDVY vs MAINGGDVY vs ABBVGGDVY vs MRKGGDVY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.